A quaternary-care hospital in Abu Dhabi with first-party GLP-1 and anti-obesity pharmacotherapy treatment pages.
Availability does not establish approval or effectiveness. Ask for the exact active ingredient, product registration, indication, prescriber, dispensing source, risks, alternatives, and follow-up plan.
Burjeel Medical City publishes first-party treatment pages for Wegovy semaglutide, GLP-1 receptor agonists and anti-obesity pharmacotherapy. Product suitability, exact indication and UAE registration should be verified for the individual medicine.
Burjeel Medical City's public GLP-1 treatment pages do not list medicine or programme prices.
Request an itemised written quote that separates consultation, testing, medicine, monitoring and follow-up costs.
Price information is attributed to the clinic and may change. It does not establish medical approval, product registration, effectiveness or the total cost of care.
These labels assess the named molecule, not the clinic’s particular product, protocol or marketing claim. UAE registration remains product and indication specific.
| Peptide | Category | Evidence | Approval note | Editorial assessment |
|---|---|---|---|---|
| GIP-GLP-1 dual agonists | Experimental compound | Limited | Exact product and status require verification | The clinic names this compound, but its exact formulation, intended use, evidence and UAE registration must be checked independently. |
| GLP-1 receptor agonists | Experimental compound | Limited | Exact product and status require verification | The clinic names this compound, but its exact formulation, intended use, evidence and UAE registration must be checked independently. |
| Semaglutide | Prescription medicine | High | Product and indication specific | Supported by substantial human evidence for specific approved metabolic indications. Verify the exact UAE-registered brand and intended use. |
Confirm current clinic and department hours with Burjeel Medical City
+971 800 23Compare clinical assessment, product traceability, informed consent, monitoring, adverse-event support, and alternatives—not marketing claims.
Is this information outdated? Send the editorial team a correction.Clinics cannot pay to change directory order or evidence classifications.